Tech Center 1600 • Art Units: 1614 1629
This examiner grants 27% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19224606 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDER | Non-Final OA | Brown University |
| 17072080 | TANK-MIX FORMULATIONS | Final Rejection | SYNGENTA PARTICIPATIONS AG |
| 18605928 | THERAPEUTIC AGENT FOR OCULAR FUNDUS DISEASE | Non-Final OA | KOWA COMPANY, LTD. |
| 17053223 | MEDICAMENT USEFUL FOR CARDIOVASCULAR DISEASE | Non-Final OA | KOWA COMPANY, LTD. |
| 17748354 | MITORIBOSCINS: MITOCHONDRIAL-BASED THERAPEUTICS TARGETING CANCER CELLS, BACTERIA, AND PATHOGENIC YEAST | Non-Final OA | LUNELLA BIOTECH, INC. |
| 17628948 | EZH2 INHIBITION IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS | Final Rejection | Constellation Pharmaceuticals, Inc. |
| 18224107 | USE OF PQQ AND DERIVATIVE THEREOF | Non-Final OA | GUANGZHOU HUTONGYOUWU BIOTECHNOLOGY CO., LTD |
| 18182511 | METHOD OF PREVENTING COCHLEAR DISEASE, DISORDER OR CONDITION USING (+)-AZASETRON | Final Rejection | SENSORION |
| 17911328 | METHODS OF TREATING ILLNESSES CAUSED BY CORONAVIRUS, SWINE FLU AND AVIAN FLU | Non-Final OA | CMTx Biotech Inc. |
| 17709710 | TOPICAL FORMULATIONS OF 5-ALPHA-REDUCTASE INHIBITORS AND USES THEREOF | Non-Final OA | Varsona Therapeutics, Inc. |
| 17675805 | STABLE CANNABINOID FORMULATIONS | Non-Final OA | Fresh Cut Development, LLC |
| 17546342 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | Final Rejection | LA PharmaTech Inc. |
| 17430168 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | Non-Final OA | MIRUM PHARMACEUTICALS, INC. |
| 17274726 | Use of CFTR Modulators For Treating Cerebrovascular Conditions | Final Rejection | Qanatpharma AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy